Literature DB >> 9517957

In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas.

C M Bébéar1, H Renaudin, A Boudjadja, C Bébéar.   

Abstract

The in vitro activity of the fluoroquinolone BAY 12-8039 against 66 strains of different mycoplasma species and 30 strains of Ureaplasma urealyticum was compared with those of three other antimicrobial agents. BAY 12-8039 at 0.5 microg/ml inhibited 100% of all the mycoplasmal and ureaplasmal strains tested. The minimal bactericidal concentrations of BAY 12-8039 increased only two- to eightfold compared to the MICs. Furthermore, they were comparable to those of sparfloxacin and lower than those of doxycycline and clarithromycin.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9517957      PMCID： PMC105523     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

2.  Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes.

Authors:  K E Aldridge; D S Ashcraft
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

3.  In vitro susceptibility of mycoplasmas to a new quinolone, BAY Y 3118.

Authors:  H Renaudin; C Bébéar
Journal:  Drugs       Date:  1995       Impact factor: 9.546

4.  In vitro activity of BAY 12-8039, a new fluoroquinolone.

Authors:  J M Woodcock; J M Andrews; F J Boswell; N P Brenwald; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

5.  Characterization of Mycoplasma hominis mutations involved in resistance to fluoroquinolones.

Authors:  C M Bebear; J M Bové; C Bebear; J Renaudin
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

6.  In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae.

Authors:  M Kaku; K Ishida; K Irifune; R Mizukane; H Takemura; R Yoshida; H Tanaka; T Usui; K Tomono; N Suyama
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

7.  In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.

Authors:  K B Waites; L B Duffy; T Schmid; D Crabb; M S Pate; G H Cassell
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

8.  Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

9.  [Comparative activity of minocycline and doxycycline on mycoplasmas pathogenic for man].

Authors:  C Bebear; P Cantet; H Renaudin; C Quentin
Journal:  Pathol Biol (Paris)       Date:  1985-06
  9 in total
  18 in total

1.  In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae.

Authors:  M Takahata; M Shimakura; R Hori; K Kizawa; Y Todo; S Minami; Y Watanabe; H Narita
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 2.  Quinolones in sexually transmitted diseases: state of the art.

Authors:  G L Ridgway
Journal:  Drugs       Date:  1999       Impact factor: 9.546

3.  Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers.

Authors:  J Lettieri; R Vargas; V Agarwal; P Liu
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline.

Authors:  Jutta Wagner; Miriam Jabbusch; Martin Eisenblätter; Helmut Hahn; Constanze Wendt; Ralf Ignatius
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

Review 5.  Concurrent gonococcal and chlamydial infection: how best to treat.

Authors:  A J Robinson; G L Ridgway
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

6.  Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas.

Authors:  C M Bebear; H Renaudin; A Bryskier; C Bebear
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

7.  In vitro susceptibilities of Mycoplasma hominis to six fluoroquinolones as determined by E test.

Authors:  K B Waites; K C Canupp; G E Kenny
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 8.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2008-07-28       Impact factor: 5.191

10.  In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas.

Authors:  S Pereyre; H Renaudin; C Bébéar; C M Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.